Antibody Drug Conjugate News and Research

RSS
Study finds dramatic increase in acute throat infection admissions in England

Study finds dramatic increase in acute throat infection admissions in England

MRI method ‘cuts breast cancer false‑positives’

MRI method ‘cuts breast cancer false‑positives’

ADI introduces octal ultrasound receiver with on-chip JESD204B serial interface

ADI introduces octal ultrasound receiver with on-chip JESD204B serial interface

Water diffusion measurements with MRI could decrease false-positive breast cancer results, biopsies

Water diffusion measurements with MRI could decrease false-positive breast cancer results, biopsies

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Bruker launches BioPharmaCompass 1.1 software

Bruker launches BioPharmaCompass 1.1 software

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Obesity and heart disease risk in children: an interview with Joana Kist-van Holthe

Obesity and heart disease risk in children: an interview with Joana Kist-van Holthe

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

ADCT, CRT sign agreements to develop ADCs against cancer

ADCT, CRT sign agreements to develop ADCs against cancer

AbGenomics raises $11 million in current financing round

AbGenomics raises $11 million in current financing round

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Investigational drug slows metastatic breast cancer progression

Investigational drug slows metastatic breast cancer progression

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Telit CC864-DUAL cellular module to connect next generation MCOT from CardioNet

Telit CC864-DUAL cellular module to connect next generation MCOT from CardioNet

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.